- Home
- OXBR vs VYNE Comparison
OXBR vs VYNE Comparison
Compare OXBR & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXBR | VYNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 12.5M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OXBR | VYNE |
|---|---|---|
| Price | $1.25 | $0.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 14.7M |
| Earning Date | 11-06-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,423,000.00 | $524,000.00 |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $1.12 | $0.28 |
| 52 Week High | $5.81 | $3.08 |
Technical Indicators
Market Signals| Indicator | OXBR | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 62.32 |
| Support Level | $1.22 | $0.56 |
| Resistance Level | $1.34 | $0.58 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 30.00 | 34.33 |
Price Performance
Historical ComparisonAbout OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.